JTCR 016

Drug Profile

JTCR 016

Alternative Names: High-affinity WT1-specific TCR T cells - Juno Therapeutics; HLA-A2/WT1-specific TCR T cells - Juno Therapeutics; JTCR016; WT1 TCR-transduced T-cell therapy - Juno Therapeutics; WT1-sensitised T cells - Juno Therapeutics

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator Juno Therapeutics
  • Developer Fred Hutchinson Cancer Research Center; Juno Therapeutics
  • Class Cancer vaccines; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Mesothelioma; Myelodysplastic syndromes; Non-small cell lung cancer

Most Recent Events

  • 22 Mar 2017 Juno Therapeutics plans a third phase I/II trial for Acute myeloid leukaemia in USA
  • 20 Apr 2016 Positive initial efficacy and adverse events data from a phase I/II trial in Non-small cell lung cancer and Mesothelioma released by Juno Therapeutics
  • 01 Dec 2012 Phase-I/II clinical trials in Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top